item management s discussion and analysis of financial condition and results of operations results of operations years ended december  and corporate revenues 
for the year ended december   total revenue increased million from million to million 
this increase was the result of a million increase in product revenue offset by a million decrease in other revenues 
see product sales and other revenues 
product sales 
for the year ended december   product sales increased million from million to million primarily as a result of new product acquisitions in the us and the united kingdom in and sales in the us increased from million to million as a result of product acquisitions and licensing activities 
tigan and eminase  acquired from smithkline beecham  and noroxin licensed from merck in  added million 
this increase was offset by a million decline in the sales of all other prescription and nonprescription products 
sales of the company s united kingdom subsidiary  monmouth pharmaceuticals  ltd  increased million from million to million 
this increase is primarily the result of the product acquisition of maxolon from smithkline beecham 
sales of the company s canadian subsidiary  roberts pharmaceutical canada  inc  decreased slightly to million from million primarily as a result of a decline in demand for the company s over the counter nonprescription pharmaceutical products 
other revenues 
other revenues result from licensing activities undertaken by the company and represent revenues from separate transactions in and for the year ended december   other revenues decreased million from million to 
million primarily as a result of a decline in licensing activities 
cost of sales 
for the year ended december   cost of sales amounted to of product sales a percentage point increase as compared to the prior year 
as a result  gross profit as a percentage of sales decreased from to 
this increase in cost of sales as a percentage of product sales and related decrease in gross profit percentage is primarily the result of the addition of noroxin to the company s product mix as well as a decline in sales of higher margin products in the us noroxin  which accounted for of the company s product sales in  has a significantly lower gross profit margin than the other core pharmaceutical products sold by the company 
in the foreseeable future  the company expects that noroxin will continue to provide a substantial part of the company s product sales and  accordingly  the company expects that cost of sales and gross profit as a percentage of sales will be similarly impacted 
research and development 
research and development expenses decreased by million to million during the year ended december  as compared to the prior year 
the decrease is due to a reduced level of expenditure required to support the company s development programs for agrelin and proamantine 
marketing and administrative expenses 
for the year ended december   marketing and administrative expenses increased million from million to million in larger part as a function of the significant increases in sales and development programs in connection with the acquisition and commencement of sales of tigan  eminase and noroxin during marketing expenses increased million as a result of increased promotional and sales activities for new products and the expansion and training of the company s sales forces in the us  canada and the united kingdom 
included in administrative expenses is amortization of intangibles relating to product acquisitions 
for the year ended december   this expense was million  an increase of 
million from million recorded in interest income and expense 
for the year ended december   interest income decreased from million to million as a result of a decrease in invested marketable securities 
interest expense decreased from million to million primarily as a result of a decrease in long term debt from income taxes 
for the year ended december   income taxes on continuing operations decreased to million from million in primarily as a result of a decline in income 
the company s effective tax rate of is higher than the normal statutory rate primarily as a result of the company s inability to recognize the tax benefit of foreign net operating loss carry forwards 
the company s effective tax rate for continuing operations should approximate a normal statutory rate 
income from continuing operations 
for the year ended december  net income from continuing operations was million  which represents a decrease of million from those same business operations during certain of the company s business operations were not discontinued in and  accordingly  the company s consolidated statements of operations for and have been restated to reflect income and loss from the company s continuing operations and discontinued operations during those years 
see notes to consolidated financial statements note the company believes that the decline in net income from continuing operations from to is attributable to a number of factors  including i a decline in demand for certain of the company s existing pharmaceutical products  particularly norethin  nitrodisc  salutensin and the company s over the counter nonprescription pharmaceutical products  ii an unanticipated delay in the closing of the company s agreement with merck to distribute noroxin and the diversion of the company s sales force from the promotion of existing products to allow for sales training related to noroxin  iii revenues from the sale of tigan and eminase during the first quarter of prior to their acquisition by the company  during which time the company was distributing such products subject to distribution agreements with smithkline beecham  were not accounted for as revenues by the company  but instead as a million reduction in the purchase price paid by the company for these products  iv the increase in cost of sales as a result of the higher costs related to the sale of noroxin and the growing importance of noroxin in the company s product mix  and v the costs associated with increasing the company s sales force by more than in in order to promote tigan  eminase and noroxin and the fact that the sale of such products did not commence until the end of the first quarter of discontinued operations 
in connection with the company s decision to divest certain non core  nonpharmaceutical business operations  the company announced  in august  its plan to discontinue and divest homecare 
in march  the company announced its plan to discontinue and divest vrg  a contract research organization 
the company expects the sales of homecare and vrg will be completed in and will result in a loss to the company at closing 
accordingly  the company has charged current operations with the estimated loss on discontinuing homecare and vrg of million 
the company has also reclassified its consolidated financial statements to report separately the net assets expected to be realized and operating results of its discontinued operations 
see notes to consolidated financial statements note the company s reported loss on discontinued operations represents the company s best estimates of the amounts expected to be realized on the sale of its discontinued operations 
the amounts the company will realize could differ materially from those amounts assumed by the company in estimating the loss on disposal reported in the company s financial statements 
years ended december  and product sales 
for the year ended december   product sales increased million from million to million primarily as a result of product acquisitions in sales in the us increased from million to million 
salutensin  colace  peri colace and other otc products acquired from bristol myers squibb in added million in the period 
sales of the company s canadian subsidiary  roberts pharmaceutical canada  inc  increased million from million to million primarily as a result of product acquisitions in from glaxo canada and bristol myers squibb 
sales of the company s united kingdom subsidiary  monmouth pharmaceuticals  ltd  amounted to million in the current period  a million increase from the comparable period 
this increase is primarily the result of the product acquisition of maxolon from smithkline beecham 
other revenues 
other revenues result from licensing activities undertaken by the company and represent revenues from separate transactions in and in the year ended december   other revenues decreased 
million from million to million 
cost of sales 
for the year ended december   cost of sales amounted to of product sales  a percentage point decrease as compared to the prior year 
the decrease in cost of sales as a percentage of sales is the result of the company s product mix  that is  increased sales of prescription products as well as prescription product sales comprising a greater percentage of total product sales 
as a result  gross profit as a percentage of sales increased from to 
research and development 
research and development expenses increased by million to million during the year ended december  as compared to the prior year 
the percentage is due to the company s continued expansion of its late stage development programs for agrelin  maxivent  and dirame 
increased costs related primarily to these programs include payments to research scientists and clinical investigators  cost of drug supplies  increased research and development staff and expenses related to monitoring clinical research sites 
marketing and administrative expenses 
for the year ended december   marketing and administrative expenses increased million from the million incurred in the prior year period in large part as a function of the significant increases in sales and development programs 
marketing expenses increased million as a result of increased promotional and sales activities for new products and the expansion and training of sales forces in the united states and canada 
included in administration expenses is amortization of intangible assets related to product and company acquisitions 
for the year ended december   this expense was million  a million increase over interest income and expense 
interest income increased from million to million as a result of the investment of the proceeds of the company s october common stock offering 
interest expense increased 
million from million primarily as a result of the amortization of discounts on non interest bearing notes issued in connection with product acquisitions in income taxes 
for the year ended december   income taxes increased to million 
the company s effective tax rate of percent is lower than the normal statutory rate primarily as a result of recognizing the tax benefit of federal  state and foreign net operating loss carryforwards and other credits 
liquidity and capital resources in the year ended december   operating cash inflows amounted to million as a result of net loss offset by non cash charges and increased by working capital requirements due to increased sales activity 
as of december   the company had cash  cash equivalents and marketable securities of million 
cash outflows from operations amounted to 
million in and cash inflows from operations in amounted to million  resulting primarily from the company s development programs and working capital requirements for sales of acquired products 
the company s funding requirements will depend on a number of factors  including the company s development programs  product acquisitions  the level of resources required for the expansion of marketing capabilities  increased investment in accounts receivable and inventory which may arise from increased sales levels  competitive and technological developments  the timing and cost of obtaining required regulatory approvals for new products  relationships with parties to collaborative agreements and the success of its acquisition activities 
the company will use its existing cash and securities balances and cash generated from operations to fund its operating activities and its near term and long term debt obligations from previous product acquisitions 
in consideration of certain information furnished by the company to the seller of certain product rights to the company  the seller agreed to defer to  million of the company s long term debt obligations which was due and payable in based upon its present plans  the company believes that it may require additional funding in fiscal if additional funds are required  the company believes that it has various alternative funding sources including bank debt  private debt financing  public and private equity financing and the sale or licensing of product rights 
cash equivalents and marketable securities currently consist of immediately available money market fund balances and investment grade securities 
capital expenditures 
expenditures for fixed assets relate primarily to the relocation and expansion of office facilities in the united states by means of a purchase of an office facility and a combination office and warehouse facility 
in anticipation of future growth  the company relocated its corporate headquarters and principal operating facilities into these expanded facilities in the third quarter of capital expenditures are not expected to be significant in the near term 
foreign currency fluctuations 
the company has subsidiary operations and performs certain development activities outside of the united states 
as a result  the company is subject to fluctuations in reported revenues and costs reported in united states dollars as a consequence of changing currency exchange rates  especially rates for the british pound 
concentration of credit risk 
the company markets prescription pharmaceuticals primarily to wholesale drug distributors  retail pharmacies  managed healthcare organizations and physicians in the united states and abroad 
the company performs certain credit evaluation procedures and does not require collateral 
the company maintains reserves for estimated credit losses 
inflation 
although at reduced levels in recent years  inflation continues to apply upward pressure on the cost of goods and services used by the company 
however  the company believes that the net effect of inflation on its operations has been minimal during the past three years 

